InsiderTradesSIGMA

InsidersTradesSigma

← Executives ★ Sign in to follow

HB

Hagen Brett R

Directeur Comptable

OtherM

Allovir, Inc.Kalaris Therapeutics, Inc.

Cumul. flow

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

€166,985

▼ Sales (38 ops.)

Insider track record

Executive

Disclosed buys

0

Disclosed sells

38

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Explore the complete record of transactions filed by Hagen Brett R, Directeur Comptable. Officer active across 2 companies, notably Allovir, Inc.. In total, 42 reports have been recorded. Breakdown: 0 buy · 38 sells. Total volume traded: €167k. History available since 20 January 2022. The latest transaction was disclosed on 20 March 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.

Companies and markets linked to Hagen Brett R

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Allovir, Inc. (US)Kalaris Therapeutics, Inc. (US)

Declarations42 total

▼

Chief Accounting OfficerExecutives20 Mar 2026Kalaris Therapeutics, Inc.

$12,86925SEC ↗

1,915 shares@ US$6.7259.6% of flowCommon StockSEC:0001193125-26-119707:0

▼

Chief Accounting OfficerExecutives26 Mar 2025Kalaris Therapeutics, Inc.

$8,13527SEC ↗

907 shares@ US$8.9693100.0% of flowCommon StockSEC:0000950170-25-046263:0

▼

Chief Accounting OfficerExecutives21 Feb 2025Allovir, Inc.

96 shares@ US$10.07580.6% of flowCommon StockSEC:0000950170-25-025633:0

▼

Chief Accounting OfficerExecutives23 Jan 2025Allovir, Inc.

32 shares@ US$9.45380.2% of flowCommon StockSEC:0000950170-25-009204:0

▼

Chief Accounting OfficerExecutives10 Jan 2025Allovir, Inc.

332 shares@ US$0.44010.1% of flowCommon StockSEC:0000950170-25-004833:0

▼

Chief Accounting OfficerExecutives19 Nov 2024Allovir, Inc.

554 shares@ US$0.54850.2% of flowCommon StockSEC:0000950170-24-129263:0

▼

Chief Accounting OfficerExecutives5 Nov 2024Allovir, Inc.

$1,43137SEC ↗

1,655 shares@ US$0.86490.8% of flowCommon StockSEC:0000950170-24-122334:0

▼

Chief Accounting OfficerExecutives21 Oct 2024Allovir, Inc.

479 shares@ US$0.7790.2% of flowCommon StockSEC:0000950170-24-116646:0

▼

Chief Accounting OfficerExecutives3 Oct 2024Allovir, Inc.

301 shares@ US$0.81480.1% of flowCommon StockSEC:0000950170-24-112911:0

▼

Chief Accounting OfficerExecutives19 Aug 2024Allovir, Inc.

544 shares@ US$0.75950.2% of flowCommon StockSEC:0000950170-24-099104:0

▼

Chief Accounting OfficerExecutives5 Aug 2024Allovir, Inc.

$1,24337SEC ↗

1,692 shares@ US$0.73480.7% of flowCommon StockSEC:0000950170-24-092806:0

▼

Chief Accounting OfficerExecutives19 Jul 2024Allovir, Inc.

479 shares@ US$0.75010.2% of flowCommon StockSEC:0000950170-24-085670:0

▼

Chief Accounting OfficerExecutives22 Jul 2024Allovir, Inc.

481 shares@ US$0.73920.2% of flowCommon StockSEC:0000950170-24-085670:1

▼

Chief Accounting OfficerExecutives2 Jul 2024Allovir, Inc.

304 shares@ US$0.720.1% of flowCommon StockSEC:0000950170-24-081515:0

▼

Chief Accounting OfficerExecutives17 May 2024Allovir, Inc.

541 shares@ US$0.74930.2% of flowCommon StockSEC:0000950170-24-062983:0

▼

Chief Accounting OfficerExecutives3 May 2024Allovir, Inc.

$1,27137SEC ↗

1,597 shares@ US$0.7960.7% of flowCommon StockSEC:0000950170-24-054510:0

▼

Chief Accounting OfficerExecutives19 Apr 2024Allovir, Inc.

473 shares@ US$0.75060.2% of flowCommon StockSEC:0000950170-24-046906:0

▼

Chief Accounting OfficerExecutives22 Apr 2024Allovir, Inc.

480 shares@ US$0.750.2% of flowCommon StockSEC:0000950170-24-046906:1

▼

Chief Accounting OfficerExecutives2 Apr 2024Allovir, Inc.

281 shares@ US$0.7720.1% of flowCommon StockSEC:0000950170-24-041811:0

▼

Chief Accounting OfficerExecutives20 Feb 2024Allovir, Inc.

494 shares@ US$0.69520.2% of flowCommon StockSEC:0000950170-24-018780:0

▼

Chief Accounting OfficerExecutives8 Feb 2024Allovir, Inc.

$7,49437SEC ↗

11,150 shares@ US$0.67214.3% of flowCommon StockSEC:0000950170-24-013491:0

▼

Chief Accounting OfficerExecutives5 Feb 2024Allovir, Inc.

$3,88137SEC ↗

5,792 shares@ US$0.672.2% of flowCommon StockSEC:0000950170-24-011770:0

▼

Chief Accounting OfficerExecutives23 Jan 2024Allovir, Inc.

901 shares@ US$0.67080.3% of flowCommon StockSEC:0000950170-24-007404:0

▼

Chief Accounting OfficerExecutives4 Jan 2024Allovir, Inc.

310 shares@ US$0.6390.1% of flowCommon StockSEC:0000950170-24-002934:0

▼

Chief Accounting OfficerExecutives27 Dec 2023Allovir, Inc.

$20,83838SEC ↗

28,335 shares@ US$0.735411.8% of flowCommon StockSEC:0000950170-24-000428:0

25 of 42 declarations

About Hagen Brett R

Hagen Brett R is Directeur Comptable. He has filed 42 disclosures in total, and in the sampled recent disclosures they are all sales, totaling EUR 166985 between 2022-01-24 and 2026-03-23. The companies mentioned in these disclosures are Allovir, Inc. and Kalaris Therapeutics, Inc.